Kiran Mazumdar-Shaw criticized the governments for neglecting basic amenities in wealthy Indian cities like Bengaluru and ...

Her remarks were triggered by a broader conversation on India’s urban readiness, where she reposted a message questioning ...

Biocon plans to launch a biosimilar to Regeneron’s blockbuster eye disease drug Eylea ($10 billion in 2024 sales) later this year. She hopes to spin off Biocon Biologics into a separate public ...

The shares of biopharmaceutical firm Biocon fell as much as 2.04 per cent in Tuesday's trading session, figuring among top ...

Bengaluru: Biocon Biologics Limited, a fully integrated global biosimilars company and a subsidiary of Biocon Limited, has ...

Karnataka: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd., has received ...

Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years ...

Naair will report to CEO Shreehas Tambe and joins the Executive Leadership Team; Seema Ahuja to transition to a new role in ...

Deepali brings over 30 years of extensive experience in brand building, marketing, and corporate reputation management across ...

Biocon's subsidiary, Biocon Biologics, has introduced Nepexto, a biosimilar to Enbrel (Etanercept), in Australia for treating ...

BENGALURU: Biocon Biologics, a subsidiary of Biocon, on Tuesday announced that it has successfully completed its multi-billion-dollar acquisition of the global biosimilars business of its partner ...